A MDP Model for Breast and Ovarian Cancer Intervention Strategies for BRCA1/2 Mutation Carriers

被引:15
|
作者
Abdollahian, Mehrnaz [1 ]
Das, Tapas K. [1 ]
机构
[1] Univ S Florida, Dept Ind & Management Syst Engn, Tampa, FL 33620 USA
关键词
BRCA1/2; mutations; hereditary breast and ovarian cancer; intervention strategies; Markov decision process (MDP); COST-EFFECTIVENESS; PREVENTION STRATEGIES; DECISION-ANALYSIS; WOMEN; SURVIVAL; SURGERY; RISK; TOOL;
D O I
10.1109/JBHI.2014.2319246
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
Purpose: Women with BRCA1/2 mutations have higher risk for breast and ovarian cancers. Available intervention actions include prophylactic surgeries and breast screening, which vary significantly in cost, cancer prevention, and in resulting death from other causes. We present a model designed to yield optimal intervention strategies for mutation carriers between the ages of 30 and 65 and any prior intervention history. Methods: A Markov decision process (MDP) model is developed that considers yearly state transitions for the mutation carriers and state dependent intervention actions. State is defined as a vector comprising mutation type, health states, prior intervention actions, and age. A discounted value iteration algorithm is used to obtain optimal strategies from the MDP model using both cost and quality-adjusted life years (QALYs) as rewards. Results: The results from MDP model show that for 30-year-old women with BRCA1 mutation and no prior intervention history, the cost-optimal strategy is a combination of prophylactic mastectomy (PM) and prophylactic oophorectomy (PO) at age 30 with no screening afterwards. Whereas, the QALYs-optimal strategy suggests PO at age 30 and PM at age 50 with screening afterwards. For BRCA2 mutation carriers at age 30, the cost-optimal strategy is PO at age 30, PM at age 40, and yearly screening only after age 56. Corresponding QALYs-optimal strategy is PM at age 40 with screening. Strategies for all other ages (31 to 65) are obtained and presented. It is also demonstrated that the cost-optimal strategies offer near maximum survival rate and near minimum cancer incidence rates by age 70, when compared to other ad hoc strategies.
引用
收藏
页码:720 / 727
页数:8
相关论文
共 50 条
  • [21] Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers
    Derks-Smeets, I.
    Schrijver, L.
    De Die-Smulders, C.
    Tjan-Heijnen, V.
    Van Golde, R.
    Caanen, B.
    Rookus, M.
    Van Leeuwen, F.
    Gomez-Garcia, E.
    HUMAN REPRODUCTION, 2018, 33 : 81 - 82
  • [22] Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers
    Inge A. P. Derks-Smeets
    Lieske H. Schrijver
    Christine E. M. de Die-Smulders
    Vivianne C. G. Tjan-Heijnen
    Ron J. T. van Golde
    Luc J. Smits
    Beppy Caanen
    Christi J. van Asperen
    Margreet Ausems
    Margriet Collée
    Klaartje van Engelen
    C. Marleen Kets
    Lizet van der Kolk
    Jan C. Oosterwijk
    Theo A. M. van Os
    Matti A. Rookus
    Flora E. van Leeuwen
    Encarna B. Gómez García
    British Journal of Cancer, 2018, 119 : 357 - 363
  • [23] Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers
    Hughes, DJ
    Ginolhac, SM
    Coupier, I
    Corbex, M
    Bressac-de-Paillerets, B
    Chompret, A
    Bignon, YJ
    Uhrhammer, N
    Lasset, C
    Giraud, S
    Hardouin, A
    Berthet, P
    Peyrat, JP
    Fournier, J
    Nogues, C
    Lidereau, R
    Muller, D
    Fricker, JP
    Longy, M
    Toulas, C
    Guimbaud, R
    Maugard, C
    Olschwang, S
    Yannoukakos, D
    Durocher, F
    Moisan, AM
    Simard, J
    Mazoyer, S
    Lynch, HT
    Szabo, C
    Lenoir, GM
    Goldgar, DE
    Stoppa-Lyonnet, D
    Sinilnikova, OM
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (01) : 265 - 267
  • [24] Hereditary breast and ovarian cancer:: primary and secondary prevention for BRCA1 and BRCA2 mutation carriers
    Llort, Gemma
    Blanco, Merce Peris e Ignacio
    MEDICINA CLINICA, 2007, 128 (12): : 468 - 476
  • [25] Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
    Peterlongo, Paolo
    Chang-Claude, Jenny
    Moysich, Kirsten B.
    Rudolph, Anja
    Schmutzler, Rita K.
    Simard, Jacques
    Soucy, Penny
    Eeles, Rosalind A.
    Easton, Douglas F.
    Hamann, Ute
    Wilkening, Stefan
    Chen, Bowang
    Rookus, Matti A.
    Schmidt, MarjankaK.
    van der Baan, Frederieke H.
    Spurdle, Amanda B.
    Walker, Logan C.
    Lose, Felicity
    Maia, Ana-Teresa
    Montagna, Marco
    Matricardi, Laura
    Lubinski, Jan
    Jakubowska, Anna
    Garcia, Encarna B. Gomez
    Olopade, Olufunmilayo I.
    Nussbaum, Robert L.
    Nathanson, Katherine L.
    Domchek, Susan M.
    Rebbeck, Timothy R.
    Arun, Banu K.
    Karlan, Beth Y.
    Orsulic, Sandra
    Lester, Jenny
    Chung, Wendy K.
    Miron, Alex
    Southey, Melissa C.
    Goldgar, David E.
    Buys, Saundra S.
    Janavicius, Ramunas
    Dorfling, Cecilia M.
    van Rensburg, Elizabeth J.
    Ding, Yuan Chun
    Neuhausen, Susan L.
    Hansen, Thomas V. O.
    Gerdes, Anne-Marie
    Ejlertsen, Bent
    Jonson, Lars
    Osorio, Ana
    Martinez-Bouzas, Cristina
    Benitez, Javier
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2015, 24 (01) : 308 - 316
  • [26] The psychological impact of breast and ovarian cancer preventive options in BRCA1 and BRCA2 mutation carriers
    Borreani, C.
    Manoukian, S.
    Bianchi, E.
    Brunelli, C.
    Peissel, B.
    Caruso, A.
    Morasso, G.
    Pierotti, M. A.
    CLINICAL GENETICS, 2014, 85 (01) : 7 - 15
  • [27] Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers
    Ramus, Susan J.
    Antoniou, Antonis C.
    Kuchenbaecker, Karoline B.
    Soucy, Penny
    Beesley, Jonathan
    Chen, Xiaoqing
    McGuffog, Lesley
    Sinilnikova, Olga M.
    Healey, Sue
    Barrowdale, Daniel
    Lee, Andrew
    Thomassen, Mads
    HUMAN MUTATION, 2012, 33 (04) : 690 - 702
  • [28] Pregnancy after breast cancer in BRCA1/2 mutation carriers
    Jelena Maksimenko
    Arvīds Irmejs
    Jānis Gardovskis
    Hereditary Cancer in Clinical Practice, 20
  • [29] Breast cancer growth rates in BRCA1/2 mutation carriers
    Bosse, K.
    Gossmann, A.
    Rhiem, K.
    Warm, M.
    Schmutzler, R. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [30] Pregnancy after breast cancer in BRCA1/2 mutation carriers
    Maksimenko, Jelena
    Irmejs, Arvids
    Gardovskis, Janis
    HEREDITARY CANCER IN CLINICAL PRACTICE, 2022, 20 (01)